- recruitingPHASE3
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
This study is testing a new medicine called sapablursen for people with Polycythemia Vera (PV). It aims to see if adding sapablursen to usual treatment is safe and helps control the condition better. Participants will be involved for up to three years, comparing the new medicine to a dummy treatment.
United States · Australia · Brazil - recruitingTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients with Phlebotomy Dependent Polycythemia Vera (PD-PV)
This study looks at a new medicine for people with polycythemia vera. It aims to see if the medicine can reduce how often patients need blood removed (phlebotomy) and to check if it's safe and well-tolerated.
Poland - recruitingTherapeutic use (Phase IV)
HU-F-AIM - A prospective, interventional study to evaluate HU-resistance in polycythemia vera patients who meet predictive parameters identified in the machine learning project PV-AIM
This study looks at how well a medicine called hydroxycarbamide works for people with a blood condition called polycythaemia vera. It aims to identify patients who might not respond well to this treatment from the beginning, helping doctors choose the best care.
Germany - active not recruitingPHASE3
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
This study is testing a new medicine called rusfertide for people with polycythemia vera (PV). It aims to see if rusfertide can help control symptoms and blood thickness better than current treatments, reducing the need for frequent blood draws.
United States · Australia · Austria - active not recruitingPHASE3
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
This study is testing a new way to use an approved drug, P1101, for adults with a blood condition called Polycythaemia Vera (PV). Researchers want to see how well it works and if it's safe, aiming to improve treatment for this challenging condition.
United States · Canada - active not recruitingPHASE4
CINC424A2X01B Rollover Protocol
This study is for patients already taking ruxolitinib, or ruxolitinib with panobinostat, in a previous trial, and who are still benefiting. It lets them continue their treatment and helps researchers learn more about the long-term safety of these medications.
Australia · Belgium · Bulgaria - recruiting
Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
This study looks at how a medicine called ropeginterferon alfa-2b works for adults with Polycythemia Vera (PV), a blood condition, who don't have a swollen spleen causing symptoms. It checks how people feel, if the treatment helps, and if it's safe in real-world use.
Germany - recruitingPHASE3
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
This study compares a new drug, ruxolitinib, with standard treatments (hydroxycarbamide or interferon) for people with high-risk Polycythaemia Vera. It aims to see which treatment works best as a first approach.
United Kingdom - recruiting
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
This study looks at how conditions like Polycythemia Vera and Thrombocythemia change over time. It compares people who had one condition and then developed another, to help doctors understand the diseases better and improve care for patients.
United States · Germany · Italy - recruitingPHASE3
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
This study is for people already taking a medicine called bomedemstat for certain blood cancers like thrombocythemia or myelofibrosis. It aims to gather more information over a longer time about how safe and effective bomedemstat is for those who are already benefiting from it.
United States · Australia · Hong Kong - recruitingPHASE3
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
This study compares two treatments, givinostat and hydroxyurea, for polycythemia vera (PV). It aims to see how well they work and if they are safe for patients with a high risk of blood clots. It focuses on PV caused by a specific gene change (JAK2V617F).
United States · Austria · Bulgaria